NCT04134117View on ClinicalTrials.gov

Tisagenlecleucel in Primary CNS Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

April 14, 2022

Study Completion Date

April 14, 2022

Conditions
Primary CNS LymphomaRefractory Primary CNS LymphomaRelapsed Primary CNS Lymphoma
Interventions
BIOLOGICAL

Tisagenlecleucel

One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.

Trial Locations (1)

02115

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Matthew J. Frigault, M.D.

OTHER